Advanced Healthcare Materials,
Journal Year:
2024,
Volume and Issue:
13(20)
Published: April 23, 2024
Gliomas,
the
most
prevalent
primary
brain
tumors,
pose
considerable
challenges
due
to
their
heterogeneity,
intricate
tumor
microenvironment
(TME),
and
blood-brain
barrier
(BBB),
which
restrict
effectiveness
of
traditional
treatments
like
surgery
chemotherapy.
This
review
provides
an
overview
engineered
cell
membrane
technologies
in
glioma
therapy,
with
a
specific
emphasis
on
targeted
drug
delivery
modulation
immune
microenvironment.
study
investigates
progress
membranes,
encompassing
physical,
chemical,
genetic
alterations,
improve
across
BBB
effectively
target
gliomas.
The
examination
focuses
interaction
membrane-coated
nanoparticles
(ECM-NPs)
TME
gliomas,
emphasizing
potential
modulate
behavior
enhance
therapeutic
efficacy.
further
explores
involvement
ECM-NPs
immunomodulation
techniques,
highlighting
impact
reactions.
While
facing
obstacles
related
stability
manufacturing
scalability,
outlines
forthcoming
research
directions
focused
enhancing
performance.
underscores
promise
surpassing
conventional
constraints,
proposing
novel
approaches
for
efficacious
treatment.
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: May 25, 2023
Abstract
Blood–brain
barrier
(BBB)
is
a
natural
protective
membrane
that
prevents
central
nervous
system
(CNS)
from
toxins
and
pathogens
in
blood.
However,
the
presence
of
BBB
complicates
pharmacotherapy
for
CNS
disorders
as
most
chemical
drugs
biopharmaceuticals
have
been
impeded
to
enter
brain.
Insufficient
drug
delivery
into
brain
leads
low
therapeutic
efficacy
well
aggravated
side
effects
due
accumulation
other
organs
tissues.
Recent
breakthrough
materials
science
nanotechnology
provides
library
advanced
with
customized
structure
property
serving
powerful
toolkit
targeted
delivery.
In-depth
research
field
anatomical
pathological
study
on
further
facilitates
development
brain-targeted
strategies
enhanced
crossing.
In
this
review,
physiological
different
cells
contributing
are
summarized.
Various
emerging
permeability
regulation
crossing
including
passive
transcytosis,
intranasal
administration,
ligands
conjugation,
coating,
stimuli-triggered
disruption,
overcome
obstacle
highlighted.
Versatile
systems
ranging
organic,
inorganic,
biologics-derived
their
synthesis
procedures
unique
physio-chemical
properties
summarized
analyzed.
This
review
aims
provide
an
up-to-date
comprehensive
guideline
researchers
diverse
fields,
offering
perspectives
system.
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(2), P. 1464 - 1484
Published: Jan. 10, 2023
Effective
drug
delivery
and
prevention
of
postoperative
recurrence
are
significant
challenges
for
current
glioblastoma
(GBM)
treatment.
Poor
is
mainly
due
to
the
presence
blood–brain
barrier
(BBB),
primarily
resistance
GBM
cells
chemotherapeutic
drugs
an
immunosuppressive
microenvironment.
Herein,
a
biomimetic
nanodrug
platform
based
on
endogenous
exosomes
that
could
efficiently
target
brain
without
targeting
modifications
co-deliver
pure
nanomicelles
immune
adjuvants
safe
efficient
chemo-immunotherapy
against
prepared.
Inspired
by
self-assembly
technology
small
molecules,
tanshinone
IIA
(TanIIA)
glycyrrhizic
acid
(GL),
which
inhibitors
signal
transducers
activators
transcription
3
from
traditional
Chinese
medicine
(TCM),
self-assembled
form
TanIIA-GL
(TGM).
Endogenous
serum
selected
coat
nanomicelles,
CpG
oligonucleotides,
agonists
Toll-like
receptor
9,
anchored
exosome
membrane
obtain
loaded
with
TCM
(CpG-EXO/TGM).
Our
results
demonstrate
CpG-EXO/TGM
can
bind
free
transferrin
in
blood,
prolong
blood
circulation,
maintain
intact
structures
when
traversing
BBB
cells.
In
microenvironment,
strong
anti-GBM
effect
attributed
two
factors:
(i)
highly
uptake
sufficient
intracellular
release
induce
apoptosis
(ii)
stimulation
dendritic
cell
maturation
induction
tumor-associated
macrophages
polarization
oligonucleotides
generate
responses.
Further
research
found
not
only
produce
better
efficacy
combination
temozolomide
but
also
prevent
recurrence.
Nature Communications,
Journal Year:
2023,
Volume and Issue:
14(1)
Published: July 28, 2023
Abstract
Glioblastoma
(GBM)
remains
the
most
lethal
malignant
tumours.
Gboxin,
an
oxidative
phosphorylation
inhibitor,
specifically
restrains
GBM
growth
by
inhibiting
activity
of
F
0
1
ATPase
complex
V.
However,
its
anti-GBM
effect
is
seriously
limited
poor
blood
circulation,
brain
barrier
(BBB)
and
non-specific
tissue/cell
uptake,
leading
to
insufficient
Gboxin
accumulation
at
sites,
which
limits
further
clinical
application.
Here
we
present
a
biomimetic
nanomedicine
(HM-NPs@G)
coating
cancer
cell-mitochondria
hybrid
membrane
(HM)
on
surface
Gboxin-loaded
nanoparticles.
An
additional
design
element
uses
reactive
oxygen
species
responsive
polymer
facilitate
at-site
release.
The
HM
camouflaging
endows
HM-NPs@G
with
unique
features
including
good
biocompatibility,
improved
pharmacokinetic
profile,
efficient
BBB
permeability
homotypic
dual
tumour
cell
mitochondria
targeting.
results
suggest
that
achieve
circulation
(4.90
h
versus
0.47
free
Gboxin)
(7.73%
ID/g
1.06%
shown
Gboxin).
Effective
inhibition
in
orthotopic
U87MG
patient
derived
X01
stem
xenografts
female
mice
extended
survival
time
negligible
side
effects
are
also
noted.
We
believe
represents
promising
treatment
for
tumours
potential.
Advanced Materials,
Journal Year:
2023,
Volume and Issue:
36(4)
Published: Nov. 21, 2023
Abstract
Hypoxia,
a
prominent
hallmark
of
hepatocellular
carcinoma
(HCC),
undermines
curative
outcomes,
elevates
recurrence
rates,
and
fosters
metastasis,
particularly
during
photodynamic
therapy
(PDT)
in
clinical
settings.
Studies
indicate
that
alleviating
tumor
hypoxia
enhances
PDT
efficacy.
However,
persistent
challenges,
including
suboptimal
oxygen
delivery
efficiency
absence
real‐time
feedback
on
blood
fluctuations
PDT,
considerably
impede
therapeutic
efficacy
treatment.
This
study
addresses
these
issues
using
near‐infrared‐II
(NIR‐II)
photoacoustic
(PA)
imaging
for
tumor‐targeted
controlled
release.
For
this
purpose,
biomimetic
system
designated
BLICP@O
2
is
developed,
which
utilizes
hybrid
cell
membranes
thermosensitive
liposomes
as
carriers,
incorporating
the
NIR‐II
dye
IR1048,
photosensitizer
chlorin
e6
(Ce6),
perfluorohexane.
Upon
sequential
irradiation
at
1064
690
nm,
exhibits
significant
photothermal
effects.
Photothermal
heating
triggers
release,
enhancing
effect
Ce6.
Blood
changes
are
tracked
by
multispectral
PA
imaging.
Enhanced
efficacy,
mediated
relief,
convincingly
demonstrated
both
vitro
vivo.
work
presents
an
imaging‐guided,
dual‐wavelength
programmed
cascaded
treatment
strategy
with
monitoring
imaging,
offering
valuable
insights
overcoming
challenges
PDT‐based
cancer
therapy.
Advanced Materials,
Journal Year:
2024,
Volume and Issue:
36(26)
Published: April 7, 2024
Abstract
Brain
disorders
represent
a
significant
challenge
in
medical
science
due
to
the
formidable
blood–brain
barrier
(BBB),
which
severely
limits
penetration
of
conventional
therapeutics,
hindering
effective
treatment
strategies.
This
review
delves
into
innovative
realm
biomimetic
nanodelivery
systems,
including
stem
cell‐derived
nanoghosts,
tumor
cell
membrane‐coated
nanoparticles,
and
erythrocyte
membrane‐based
carriers,
highlighting
their
potential
circumvent
BBB's
restrictions.
By
mimicking
native
properties,
these
nanocarriers
emerge
as
promising
solution
for
enhancing
drug
delivery
brain,
offering
strategic
advantage
overcoming
barrier's
selective
permeability.
The
unique
benefits
leveraging
membranes
from
various
sources
is
evaluated
advanced
technologies
fabricating
membrane‐encapsulated
nanoparticles
capable
masquerading
endogenous
cells
are
examined.
enables
targeted
broad
spectrum
therapeutic
agents,
ranging
small
molecule
drugs
proteins,
thereby
providing
an
approach
neurocare.
Further,
contrasts
capabilities
limitations
with
traditional
methods,
underlining
enable
targeted,
sustained,
minimally
invasive
modalities.
concluded
perspective
on
clinical
translation
underscoring
transformative
impact
landscape
intractable
brain
diseases.
Signal Transduction and Targeted Therapy,
Journal Year:
2025,
Volume and Issue:
10(1)
Published: Feb. 11, 2025
Abstract
Accumulated
evidence
has
implicated
the
diverse
and
substantial
influence
of
lactate
on
cellular
differentiation
fate
regulation
in
physiological
pathological
settings,
particularly
intricate
conditions
such
as
cancer.
Specifically,
been
demonstrated
to
be
pivotal
molding
tumor
microenvironment
(TME)
through
its
effects
different
cell
populations.
Within
cells,
impacts
signaling
pathways,
augments
shuttle
process,
boosts
resistance
oxidative
stress,
contributes
lactylation.
In
various
populations,
interplay
between
immune
cells
governs
processes
differentiation,
response,
surveillance,
treatment
effectiveness.
Furthermore,
communication
stromal/endothelial
supports
basal
membrane
(BM)
remodeling,
epithelial-mesenchymal
transitions
(EMT),
metabolic
reprogramming,
angiogenesis,
drug
resistance.
Focusing
production
transport,
specifically
dehydrogenase
(LDH)
monocarboxylate
transporters
(MCT),
shown
promise
Inhibitors
targeting
LDH
MCT
act
both
suppressors
enhancers
immunotherapy,
leading
a
synergistic
therapeutic
effect
when
combined
with
immunotherapy.
The
review
underscores
importance
progression
provides
valuable
perspectives
potential
approaches
that
target
vulnerability
metabolism,
highlighting
Heel
Achilles
for
cancer
treatment.
Materials Today Bio,
Journal Year:
2025,
Volume and Issue:
30, P. 101443 - 101443
Published: Jan. 5, 2025
Glioblastoma
(GBM)
is
the
most
prevalent
primary
malignant
brain
tumor,
characterized
by
a
high
mortality
rate
and
poor
prognosis.
The
blood-brain
barrier
(BBB)
blood-tumor
(BTB)
present
significant
obstacles
to
efficacy
of
tumor-targeted
pharmacotherapy,
thereby
impeding
therapeutic
potential
numerous
candidate
drugs.
Targeting
delivery
adequate
doses
drug
across
BBB
treat
GBM
has
become
prominent
research
area
in
recent
years.
This
emphasis
driven
exploration
evaluation
diverse
technologies
for
with
some
already
undergoing
clinical
trials.
review
provides
thorough
overview
advancements
challenges
targeted
treatment.
It
specifically
emphasizes
systemic
administration
strategies
assess
their
limitations
Furthermore,
this
highlights
promising
future
directions
development
intelligent
systems
aimed
at
overcoming
current
enhancing
against
GBM.
These
not
only
support
foundational
on
but
also
offer
methodological
approaches
applications.
